NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions and answers
1. Question 18: A. Dissociative disorders
Christine is a 9-year-old female who B. Post-traumatic stress disorder
presents for care after having been C. Impulse-control disorder
placed in the local foster care sys- D. Attachment disorder tem. She
has been in and out of fos- ter care for the last 4 years after her
parents were killed in an automobileaccident. Christine has been
placed in a variety of homes and residential care facilities. The
PMHNP recognizes that Christine is at high risk for:
2. Question 7: A. Caylee is at high risk for suicide
Caylee is a 5-year-old girl who is re- and precautions should be taken
ferred for evaluation by child protec- B. The hallucinations are consis-
tive services. She was recently re- tent with brief psychotic disorder or
moved from her biological family and schizophrenia
placed in foster care, as her home en- C. The history and reported
vironment was reportedly unsafe due symptoms are typical of
to conditions of extreme neglect. Her depressive dis-
foster mother reports that Caylee is D.order in young children
This is a common situation when very
quiet and withdrawn and always prepubertal children are removed
appears sad and disinterested in her from the biological parents regard-
surroundings; however, she becomes less of how dysfunctional they are
very irritable when anything unexpect- ed or unplanned occurs. The
foster motherit appeared that Caylee was halluci became very
concerned when- nating. The PMHNP considers that:
3. Question 2: A. There is a > 50% likelihood that
Debi is a 15-year-old girl who is cur- Debi's younger sibling will develop
rently being treated for depression. depressive symptoms
Her parents have been very proactive B. The mean length of major de-
and involved in her care, and Debi pressive episode in adolescents is
has achieved remission 2 months af- 4 months
ter beginning treatment with a combi- C. 20 to 40% of adolescents who
nation of pharmacotherapy and cog- have major depressive disorder
nitive behavioral therapy. While coun- will develop bipolar I within 5 years
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions
seling Debi's parents about important D. Adolescent-onset depression
issues in management, the PMHNP typically need long-term pharma-
advises that: cologic management to prevent
re- lapses
4. Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM) -
Agonist at melatonergic 1 and
melatonergic 2 receptors -
Antagonist at 5HT2C receptors -
Not FDA approved: Rx for Depres-
sion, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after
2 weeks can increase to 50
mg/day at bedtime
5. Amitriptyline (Elavil) Tricyclic antidepressant.
6. Aripiprazole (Abilify) Treatment for depression. Atypi-
cal antipsychotic. "Dopamine
stabi- lizer". Dopamine receptor
antago- nist in high concentration
and also stimulates increase of
dopamine in low concentrations.
Side effects: in- somnia, akathisia.
7. Brexpiprazole (Rexulti) Treatment for depression. Atypical
antipsychotic
8. Bupropion (Wellbutrin) Antidepressant and smoking ces-
sation aid, It can treat depres- sion
and help people quit smok- ing. It
can also prevent depression
caused by seasonal affective
disor- der (SAD).
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions and answers
9. Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg
qd.
10. Clomipramine (Anafranil) -Serotonin reuptake inhibitor
(S-RI)
-Tricyclic antidepressant (TCA) -
Parent drug is a potent serotonin
reuptake inhibitor Active
metabolite is a potent norep-
inephrine/noradrenaline reuptake
inhibitor
-Increases serotonergic neuro-
transmission by blocking the sero-
tonin reuptake pump (transporter),
-Desensitization of serotonin re-
ceptors, especially serotonin 1A
receptors
-Increases noradrenergic neuro-
transmission by blocking the nor-
epinephrine reuptake pump (trans-
porter), -Desensitization of beta
adrenergic receptors -Dopamine is
inactivated by nor- epinephrine
reuptake in the frontal cortex
-Lacks dopamine transporters -
Increases dopamine neurotrans-
mission in this part of the brain
**FDA Approved for Pediatrics in tx
Obsessive-compulsive disorder
(OCD) (ages 10 and older) *Off-
Label for Pediatric Use: De-
pression, Severe and treatment-
re- sistant, depression, Cataplexy
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions
syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take
2-8 weeks -Dosing: in
Peds/Adoles-
cents/Adults: 100-
250mg/day
Final Exam Test Questions and answers
1. Question 18: A. Dissociative disorders
Christine is a 9-year-old female who B. Post-traumatic stress disorder
presents for care after having been C. Impulse-control disorder
placed in the local foster care sys- D. Attachment disorder tem. She
has been in and out of fos- ter care for the last 4 years after her
parents were killed in an automobileaccident. Christine has been
placed in a variety of homes and residential care facilities. The
PMHNP recognizes that Christine is at high risk for:
2. Question 7: A. Caylee is at high risk for suicide
Caylee is a 5-year-old girl who is re- and precautions should be taken
ferred for evaluation by child protec- B. The hallucinations are consis-
tive services. She was recently re- tent with brief psychotic disorder or
moved from her biological family and schizophrenia
placed in foster care, as her home en- C. The history and reported
vironment was reportedly unsafe due symptoms are typical of
to conditions of extreme neglect. Her depressive dis-
foster mother reports that Caylee is D.order in young children
This is a common situation when very
quiet and withdrawn and always prepubertal children are removed
appears sad and disinterested in her from the biological parents regard-
surroundings; however, she becomes less of how dysfunctional they are
very irritable when anything unexpect- ed or unplanned occurs. The
foster motherit appeared that Caylee was halluci became very
concerned when- nating. The PMHNP considers that:
3. Question 2: A. There is a > 50% likelihood that
Debi is a 15-year-old girl who is cur- Debi's younger sibling will develop
rently being treated for depression. depressive symptoms
Her parents have been very proactive B. The mean length of major de-
and involved in her care, and Debi pressive episode in adolescents is
has achieved remission 2 months af- 4 months
ter beginning treatment with a combi- C. 20 to 40% of adolescents who
nation of pharmacotherapy and cog- have major depressive disorder
nitive behavioral therapy. While coun- will develop bipolar I within 5 years
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions
seling Debi's parents about important D. Adolescent-onset depression
issues in management, the PMHNP typically need long-term pharma-
advises that: cologic management to prevent
re- lapses
4. Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM) -
Agonist at melatonergic 1 and
melatonergic 2 receptors -
Antagonist at 5HT2C receptors -
Not FDA approved: Rx for Depres-
sion, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after
2 weeks can increase to 50
mg/day at bedtime
5. Amitriptyline (Elavil) Tricyclic antidepressant.
6. Aripiprazole (Abilify) Treatment for depression. Atypi-
cal antipsychotic. "Dopamine
stabi- lizer". Dopamine receptor
antago- nist in high concentration
and also stimulates increase of
dopamine in low concentrations.
Side effects: in- somnia, akathisia.
7. Brexpiprazole (Rexulti) Treatment for depression. Atypical
antipsychotic
8. Bupropion (Wellbutrin) Antidepressant and smoking ces-
sation aid, It can treat depres- sion
and help people quit smok- ing. It
can also prevent depression
caused by seasonal affective
disor- der (SAD).
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions and answers
9. Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg
qd.
10. Clomipramine (Anafranil) -Serotonin reuptake inhibitor
(S-RI)
-Tricyclic antidepressant (TCA) -
Parent drug is a potent serotonin
reuptake inhibitor Active
metabolite is a potent norep-
inephrine/noradrenaline reuptake
inhibitor
-Increases serotonergic neuro-
transmission by blocking the sero-
tonin reuptake pump (transporter),
-Desensitization of serotonin re-
ceptors, especially serotonin 1A
receptors
-Increases noradrenergic neuro-
transmission by blocking the nor-
epinephrine reuptake pump (trans-
porter), -Desensitization of beta
adrenergic receptors -Dopamine is
inactivated by nor- epinephrine
reuptake in the frontal cortex
-Lacks dopamine transporters -
Increases dopamine neurotrans-
mission in this part of the brain
**FDA Approved for Pediatrics in tx
Obsessive-compulsive disorder
(OCD) (ages 10 and older) *Off-
Label for Pediatric Use: De-
pression, Severe and treatment-
re- sistant, depression, Cataplexy
, NRNP 6665 – PMHNP Care Across the Lifespan I
Final Exam Test Questions
syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take
2-8 weeks -Dosing: in
Peds/Adoles-
cents/Adults: 100-
250mg/day
